Portal Diabetes announced today that it received FDA breakthrough device designation for its implantable insulin pump system.
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
A new type of brain implant may have implications for both brain research and future treatments of neurological diseases such as epilepsy.
AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions.
Scientists have identified early blood biomarkers for Parkinson’s disease, revealing a narrow window in which the condition could be detected years before symptoms appear. Parkinson’s disease affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results